Erythrodermic psoriasis (EP) is a severe form of psoriasis precipitated by numerous factors, including physical stress, infections, and drugs. The disease represents a therapeutic challenge, and little is known about its response to ustekinumab. Though the efficacy of ustekinumab has been extensively studied in chronic plaque psoriasis, no trials have been carried out in EP. We report the case of 2 patients, 1 male and 1 female, who showed EP despite being treated with etanercept and methotrexate for chronic plaque psoriasis, respectively. The patients were treated with ustekinumab at a dosage of 45 mg s.c. They showed a significant improvement in their Psoriasis Area and Severity Index score after only 4 weeks of ustekinumab therapy, and further improvements were observed throughout the treatment. In our experience, ustekinumab has been proven safe and effective, without increasing the dosage, in controlling and preventing the occurrence of erythrodermic flares. Ustekinumab therapy may therefore be considered a valid therapeutic option for the treatment of EP, even in cases where other biological agents have failed.

Saraceno, R., Talamonti, M., Galluzzo, M., Chiricozzi, A., Costanzo, A., Chimenti, S. (2013). Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases, 5(3), 254-258 [10.1159/000348645].

Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases

Saraceno R.;Talamonti M.;Galluzzo M.;Costanzo A.;Chimenti S.
2013-01-01

Abstract

Erythrodermic psoriasis (EP) is a severe form of psoriasis precipitated by numerous factors, including physical stress, infections, and drugs. The disease represents a therapeutic challenge, and little is known about its response to ustekinumab. Though the efficacy of ustekinumab has been extensively studied in chronic plaque psoriasis, no trials have been carried out in EP. We report the case of 2 patients, 1 male and 1 female, who showed EP despite being treated with etanercept and methotrexate for chronic plaque psoriasis, respectively. The patients were treated with ustekinumab at a dosage of 45 mg s.c. They showed a significant improvement in their Psoriasis Area and Severity Index score after only 4 weeks of ustekinumab therapy, and further improvements were observed throughout the treatment. In our experience, ustekinumab has been proven safe and effective, without increasing the dosage, in controlling and preventing the occurrence of erythrodermic flares. Ustekinumab therapy may therefore be considered a valid therapeutic option for the treatment of EP, even in cases where other biological agents have failed.
2013
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Anti-TNFα; Erythrodermic psoriasis; Ustekinumab
Saraceno, R., Talamonti, M., Galluzzo, M., Chiricozzi, A., Costanzo, A., Chimenti, S. (2013). Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases, 5(3), 254-258 [10.1159/000348645].
Saraceno, R; Talamonti, M; Galluzzo, M; Chiricozzi, A; Costanzo, A; Chimenti, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
eritrodermia.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 937.21 kB
Formato Adobe PDF
937.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/240900
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 13
  • ???jsp.display-item.citation.isi??? ND
social impact